ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The incidence of immune thrombocytopenia increases with older age. This population is at risk
for arterial thrombosis. Due to an increased turn-over of platelets, low-dose aspirin once
daily may be insufficient in this population to protect against arterial thrombosis. This
study is aimed at assessing the pharmacodynamics of aspirin once daily on platelet function
in these patients.